Clinical utility of a prediction tool to differentiate between breast cancer patients at high or low risk of chemotherapy-induced nausea and vomiting.
Mashari Jemaan AlzahraniGeorge DranitsarisMarta SienkiewiczLisa VandermeerMark ClemonsPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)
The PRM was able to identify patients at greater risk of significant nausea but not the other CINV endpoints. As nausea remains a pertinent issue for patients with BC, the PRM could be used to identify these patients a priori for innovative treatment strategies.